secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001171843-25-005383
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose Q2 net loss $7.0M; cash $1.3M; CSRC okays TUS dose escalation to 160 mg
------------------------------------------------------------------------------

- Net loss $7.0M ($2.76 per share) for Q2 2025, vs. $7.3M in Q2 2024; loss per share improved on higher share count.
- Cash and equivalents $1.3M as of June 30, 2025; company says cash insufficient to fund operations, relying on Hanmi loan of up to $8.5M.
- Safety Review Committee approved dose escalation of tuspetinib to 160 mg in TUS+VEN+AZA TUSCANY trial; 120 mg cohort all patients remain on study.
- All 10 enrolled subjects in TUSCANY triplet remain on treatment; CRs achieved at 40 mg and 80 mg doses across diverse AML mutations.
- Selected EY as new auditor; annual meeting reconvened for August 22, 2025 to vote on appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005383/0001171843-25-005383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005383/f8k_081325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer